Neoplasia · 2011 · 39 citations · 48 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyAngiogenesisAngiogenesis In CancerOncogenic Signaling PathwaysOncology PharmacologyPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsAnticancer ActivityAnticancer ChemotherapyAntiproliferative AgentsAntiproliferative Drug ActionApoptosis Of Endothelial CellsIrinotecan-based TherapyVascular Endothelial Growth FactorVascular Endothelial Growth Factor Receptors
AIMS: To demonstrate the synergistic antiproliferative and proapoptotic activity of irinotecan and axitinib in vitro and the improvement of the in vivo effects on angiogenesis and pancreatic cancer. METHODS: Proliferation and apoptotic assays were performed on human dermal microvascular endothelial cells and pancreas cancer (MIAPaCa-2, Capan-1) cell lines exposed to SN-38, the active metabolite of irinotecan, axitinib, or their simultaneous combination for 72 hours. ERK1/2 and Akt phosphorylation, the vascular endothelial growth factor (VEGF), VEGF receptor-2, and thrombospondin-1 (TSP-1) concentration were measured by ELISAs. ATP7A and ABCG2 gene expression was performed with real-time polymerase chain reaction and SN-38 intracellular concentrations were measured by high-performance liquid chromatography. Capan-1 xenografts in nude mice were treated with irinotecan and axitinib alone or in simultaneous combination. RESULTS: A strong synergistic effect on antiproliferative and proapoptotic activity was found with the axitinib/SN-38 combination on endothelial and cancer cells. ERK1/2 and Akt phosphorylation were significantly inhibited by lower concentrations of the combined drugs in all the cell lines. Axitinib and SN-38 combined treatment greatly inhibited the expression of the ATP7A and ABCG2 genes in endothelial and cancer cells, increasing the SN-38 intracellular concentration. Moreover, TSP-1 secretion was increased in cells treated with both drugs, whereas VEGFR-2 levels significantly decreased. In vivo administration of the simultaneous combination determined an almost complete regression of tumors and tumor neovascularization. CONCLUSIONS: In vitro results show the highly synergistic properties of simultaneous combination of irinotecan and axitinib on endothelial and pancreas cancer cells, suggesting a possible translation of this schedule into the clinics.
48
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M.L. Ebos, Christina R. Lee, William Cruz‐Muñoz et al. · Cancer Cell · 2009 · 1.7K citations · Full text
Medicine, Oncology, Pharmacology +16
Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman et al. · Journal of Clinical Oncology · 2005 · 1.6K citations · Full text
Guidelines for the welfare and use of animals in cancer research
Paul Workman, Eric O. Aboagye, Frances R. Balkwill et al. · British Journal of Cancer · 2010 · 1.4K citations · Full text
Medicine, Animal Sciences, Oncology +17
Autocrine VEGF Signaling Is Required for Vascular Homeostasis
Sunyoung Lee, Tom T. Chen, Chad L. Barber et al. · Cell · 2007 · 1K citations · Full text
Dana D. Hu‐Lowe, Helen Y. Zou, Maren L. Grazzini et al. · Clinical Cancer Research · 2008 · 628 citations
Medicine, Oncology, Pharmacology +17